Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > VERU Veru Inc > Detailed Quotes

VERU Veru Inc

Watchlist
5.900
-0.010-0.17%
Close  01/27 16:00 ET
6.000
+0.100+1.69%
Post Mkt Price 01/27 19:37 ET
High
6.090
Open
5.880
Turnover
11.05M
Low
5.810
Pre Close
5.910
Volume
1.86M
Market Cap
475.68M
P/E(TTM)
Loss
52wk High
24.550
Shares
80.62M
P/E(Static)
Loss
52wk Low
4.340
Float Cap
383.64M
Bid/Ask %
-55.56%
Historical High
24.570
Shs Float
65.02M
Volume Ratio
1.10
Historical Low
0.271
Dividend TTM
--
Div Yield TTM
--
P/B
5.88
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.86%
Amplitude
4.74%
Avg Price
5.947
Lot Size
1
Float Cap
383.64M
Bid/Ask %
-55.56%
Historical High
24.570
Shs Float
65.02M
Volume Ratio
1.10
Historical Low
0.271
Dividend TTM
--
P/B
5.88
Dividend LFY
--
Turnover Ratio
2.86%
Amplitude
4.74%
Avg Price
5.947
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.
CEO: Dr. Mitchell S. Steiner
Market: NASDAQ
Listing Date: 07/01/1990
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist